Q3 2024 Baxter International Inc Earnings Call Transcript
Key Points
- Baxter International Inc (BAX) reported a 4% sales growth in the third quarter of 2024, in line with prior guidance.
- The Medical Products & Therapies segment led with a 7% growth, driven by strong demand for the Novum IQ platform and Advanced Surgery division.
- The company achieved an adjusted earnings per share of $0.80, surpassing the guidance range of $0.77 to $0.79.
- Baxter's North Cove facility recovery efforts were ahead of schedule, with key production lines restarting sooner than expected.
- The pending sale of the Kidney Care business is progressing well, expected to close by late 2024 or early 2025, which aligns with Baxter's strategic transformation goals.
- Hurricane Helene significantly impacted Baxter's North Cove operations, leading to an estimated $200 million sales loss in the fourth quarter.
- The Healthcare Systems & Technologies segment showed only 1% growth, with challenges in the US primary care market and international sales declines.
- Pharmaceuticals segment growth was limited to 1%, with supply constraints and sales phasing issues affecting performance.
- Stranded costs from the Kidney Care business divestiture negatively impacted operating margins by 240 basis points in the third quarter.
- The company anticipates a continued negative impact from Hurricane Helene into the first quarter of 2025, affecting sales and operations.
Good morning, ladies and gentlemen, and welcome to Baxter International's third-quarter 2024 earnings conference call. (Operator Instructions)
As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
I would now like to turn the call over to Ms. Clare Trachtman, Senior Vice President, Chief Investor Relations Officer at Baxter International. Ms. Trachtman, you may now begin.
Good morning, and welcome to our third quarter 2024 earnings conference call. Joining me today are Jose Almeida, Baxter's Chairman and Chief Executive Officer; and Joel Grade, Baxter's Executive Vice President and Chief Financial Officer. On the call this morning, we will be discussing Baxter's third quarter 2024 results along with our financial outlook for the fourth quarter and full year 2024.
With that, let me
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
